Johnson & Johnson’s deal for Numab Therapeutics’ bispecific antibody NM26, slated to enter Phase II studies, comes on the ...

The potential purchase by the Japanese conglomerate could secure access to Calliditas’ IgA nephropathy therapy Tarpeyo, which ...

NS Pharma, a subsidiary of Nippon Shinyaku, announced Monday that its Duchenne muscular dystrophy candidate Viltepso failed a ...

Flagging a risk of hypoglycemia, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee on Friday did not recommend ...

With back-to-back victories in IgA nephropathy and C3 glomerulopathy, Novartis on Saturday said it is planning to make ...

AstraZeneca and Daiichi Sankyo’s investigational antibody-drug conjugate Dato-DXd failed to significantly improve overall ...

It’s 100 percent fatal, hits patients in the prime of their lives, then gets passed down to 50 percent of the next generation ...

Until compelling surface targets for lung cancer are developed, antibody-drug conjugates will fail to treat most patients ...

Approaches and targets for depression and other mental health illnesses have remained stagnant for decades. With several ...

After selling off its oral TYK2 blocker to Takeda for $4 billion, Nimbus Therapeutics has posted strong early-stage data for ...

Aiming to compete in the lucrative weight-loss drug market, Zealand Pharma on Thursday posted topline results showing its ...

Johnson & Johnson’s radiopharma candidate JNJ-6420 returned mixed results in an early-stage study, demonstrating strong ...